Fulgent Genetics, Inc. (FLGT) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Fulgent Genetics, Inc. (FLGT) Bundle
Optimize your time and improve precision with our (FLGT) DCF Calculator! With access to real Fulgent Genetics data and customizable assumptions, this tool empowers you to forecast, analyze, and evaluate Fulgent Genetics, Inc. like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 32.5 | 421.7 | 992.6 | 619.0 | 289.2 | 368.1 | 468.5 | 596.2 | 758.8 | 965.8 |
Revenue Growth, % | 0 | 1196.46 | 135.37 | -37.64 | -53.27 | 27.27 | 27.27 | 27.27 | 27.27 | 27.27 |
EBITDA | 1.7 | 290.2 | 676.0 | 221.6 | -46.6 | 119.1 | 151.6 | 192.9 | 245.5 | 312.5 |
EBITDA, % | 5.16 | 68.8 | 68.1 | 35.8 | -16.1 | 32.35 | 32.35 | 32.35 | 32.35 | 32.35 |
Depreciation | 2.5 | 3.4 | 12.2 | 36.9 | 26.1 | 18.2 | 23.2 | 29.5 | 37.6 | 47.9 |
Depreciation, % | 7.75 | 0.79936 | 1.23 | 5.96 | 9.04 | 4.95 | 4.95 | 4.95 | 4.95 | 4.95 |
EBIT | -.8 | 286.8 | 663.8 | 184.7 | -72.7 | 100.9 | 128.4 | 163.4 | 207.9 | 264.6 |
EBIT, % | -2.59 | 68.01 | 66.88 | 29.84 | -25.14 | 27.4 | 27.4 | 27.4 | 27.4 | 27.4 |
Total Cash | 70.2 | 431.9 | 935.5 | 852.9 | 424.2 | 363.9 | 463.1 | 589.4 | 750.1 | 954.7 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 6.7 | 204.1 | 143.3 | 52.7 | 57.4 | 82.3 | 104.8 | 133.3 | 169.7 | 216.0 |
Account Receivables, % | 20.61 | 48.39 | 14.44 | 8.52 | 19.86 | 22.36 | 22.36 | 22.36 | 22.36 | 22.36 |
Inventories | .3 | 16.5 | 12.2 | 4.3 | .0 | 4.9 | 6.3 | 8.0 | 10.1 | 12.9 |
Inventories, % | 0.85157 | 3.91 | 1.23 | 0.69147 | 0 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 |
Accounts Payable | 1.6 | 26.5 | 20.5 | 23.1 | 15.4 | 16.4 | 20.8 | 26.5 | 33.8 | 43.0 |
Accounts Payable, % | 4.86 | 6.28 | 2.06 | 3.73 | 5.31 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 |
Capital Expenditure | -1.3 | -36.5 | -23.8 | -18.8 | -22.2 | -19.0 | -24.2 | -30.8 | -39.2 | -49.9 |
Capital Expenditure, % | -4.05 | -8.66 | -2.4 | -3.03 | -7.68 | -5.17 | -5.17 | -5.17 | -5.17 | -5.17 |
Tax Rate, % | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 |
EBITAT | -.8 | 210.7 | 497.2 | 143.9 | -70.1 | 83.1 | 105.8 | 134.7 | 171.4 | 218.1 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -5.0 | -11.1 | 544.6 | 263.1 | -74.3 | 53.6 | 85.5 | 108.8 | 138.5 | 176.3 |
WACC, % | 11.36 | 11.34 | 11.34 | 11.35 | 11.37 | 11.35 | 11.35 | 11.35 | 11.35 | 11.35 |
PV UFCF | ||||||||||
SUM PV UFCF | 388.9 | |||||||||
Long Term Growth Rate, % | 3.00 | |||||||||
Free cash flow (T + 1) | 182 | |||||||||
Terminal Value | 2,173 | |||||||||
Present Terminal Value | 1,269 | |||||||||
Enterprise Value | 1,658 | |||||||||
Net Debt | -82 | |||||||||
Equity Value | 1,741 | |||||||||
Diluted Shares Outstanding, MM | 30 | |||||||||
Equity Value Per Share | 58.44 |
What You Will Get
- Real FLGT Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Fulgent Genetics' future performance.
- User-Friendly Design: Designed for professionals while remaining accessible to newcomers.
Key Features
- Real-Time FLGT Data: Pre-loaded with Fulgent Genetics’ historical financial metrics and future projections.
- Customizable Assumptions: Modify revenue growth rates, profit margins, WACC, tax rates, and capital expenditures as needed.
- Interactive Valuation Model: Automatically refreshes Net Present Value (NPV) and intrinsic value based on your modifications.
- Scenario Analysis: Develop various forecast scenarios to explore different valuation possibilities.
- User-Centric Interface: Intuitive, organized, and crafted for both industry professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Fulgent Genetics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Fulgent Genetics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Fulgent Genetics, Inc. (FLGT)?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for Fulgent Genetics.
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios for FLGT.
- Detailed Insights: Automatically computes Fulgent's intrinsic value and Net Present Value.
- Preloaded Data: Includes historical and projected data for accurate financial assessments.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on FLGT.
Who Should Use This Product?
- Genetics Researchers: Explore advanced genetic testing methodologies and apply them to real-world data.
- Healthcare Professionals: Integrate genetic insights into patient care and treatment planning.
- Investors: Evaluate your investment strategies and analyze valuation outcomes for Fulgent Genetics, Inc. (FLGT).
- Laboratory Analysts: Enhance your analysis with a customizable genetic testing framework.
- Biotech Entrepreneurs: Understand how established companies like Fulgent Genetics are evaluated in the market.
What the Template Contains
- Preloaded FLGT Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.